2 weeks Ago By ABMN Staff
Envestnet Asset Management Inc. reduced its stake in CONMED Co. ( NYSE:CNMD – Free Report ) by 1.
3% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 149,710 shares of the company’s stock after selling 2,015 shares during the quarter. Envestnet Asset Management Inc.
owned approximately 0.48% of CONMED worth $10,246,000 at the end of the most recent reporting period. A number of other large investors have also recently added to or reduced their stakes in the stock.
Raymond James Financial Inc. acquired a new stake in shares of CONMED in the fourth quarter worth $18,248,000. Fisher Asset Management LLC boosted its holdings in CONMED by 41.
4% during the fourth quarter. Fisher Asset Management LLC now owns 417,430 shares of the company’s stock valued at $28,569,000 after acquiring an additional 122,140 shares during the period. Wealthfront Advisers LLC acquired a new stake in shares of CONMED in the fourth quarter valued at about $5,790,000.
Allspring Global Investments Holdings LLC increased its stake in shares of CONMED by 44.5% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 223,142 shares of the company’s stock worth $15,029,000 after purchasing an additional 68,696 shares during the period.
Finally, Clearbridge Investments LLC lifted its position in shares of CONMED by 9.4% during the 4th quarter. Clearbridge Investments LLC now owns 542,966 shares of the company’s stock worth $37,161,000 after purchasing an additional 46,582 shares during the last quarter.
Wall Street Analyst Weigh In Several research analysts have commented on CNMD shares. JPMorgan Chase & Co. downgraded CONMED from an “overweight” rating to a “neutral” rating and dropped their price target for the stock from $85.
00 to $70.00 in a research report on Thursday, February 6th. Wells Fargo & Company dropped their target price on shares of CONMED from $74.
00 to $70.00 and set an “equal weight” rating on the stock in a research report on Thursday, February 6th. Needham & Company LLC reduced their price target on shares of CONMED from $97.
00 to $91.00 and set a “buy” rating for the company in a report on Thursday, February 6th. Finally, Stifel Nicolaus boosted their price objective on shares of CONMED from $72.
00 to $75.00 and gave the stock a “buy” rating in a report on Thursday, February 6th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock.
Based on data from MarketBeat, CONMED presently has a consensus rating of “Moderate Buy” and an average target price of $77.20. CONMED Trading Up 1.
0 % Shares of CNMD stock opened at $48.53 on Friday. The firm has a fifty day moving average of $58.
36 and a 200-day moving average of $65.70. The stock has a market cap of $1.
50 billion, a price-to-earnings ratio of 11.45, a P/E/G ratio of 1.83 and a beta of 1.
28. CONMED Co. has a 52-week low of $47.
25 and a 52-week high of $78.58. The company has a debt-to-equity ratio of 0.
94, a quick ratio of 1.06 and a current ratio of 2.30.
CONMED ( NYSE:CNMD – Get Free Report ) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $1.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.
20 by $0.14. CONMED had a net margin of 10.
13% and a return on equity of 14.31%. On average, equities research analysts forecast that CONMED Co.
will post 4.35 earnings per share for the current fiscal year. CONMED Dividend Announcement The business also recently declared a quarterly dividend, which was paid on Friday, April 4th.
Shareholders of record on Friday, March 14th were given a $0.20 dividend. This represents a $0.
80 dividend on an annualized basis and a yield of 1.65%. The ex-dividend date of this dividend was Friday, March 14th.
CONMED’s dividend payout ratio (DPR) is 18.87%. About CONMED ( Free Report ) CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide.
The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. See Also Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with MarketBeat.com's FREE daily email newsletter .
.
